# References of included studies

### Author-based assessment

Burls A, Clark W, Stewart T, et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess. 2002;6:1–87.

Mauskopf JA, Cates SC, Griffin AD, et al. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics. 2000;17:611–620.

Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis. 2001;33:1879–1885.

Rothberg MB, Fisher D, Kelly B, et al. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy. Arch Pediatr Adolesc Med. 2005;159:1055–1062.

### Expert-based assessment

Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics. 2001;19:293–301.

Stouthard M, Essink-Bot M, Bonsel G, et al. Disability weights for diseases in the Netherlands. Rotterdam: Erasmus University of Rotterdam; 1997.

Stratton KR, Durch JS, Lawrence RS, editors. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington (DC): [publisher unknown]; 2000.

### Self-assessment

Bilcke J, Coenen S, Beutels P. Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. PLoS One. 2014;9:e102634.

Brady B, McAuley L, Shukla VK. Economic evaluation of Zanamivir for the treatment of influenza. (Technology report; issue 13). Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2001.

Camacho A, Eames K, Adler A, et al. Estimation of the quality of life effect of seasonal influenza infection in the UK with the internet-based Flusurvey cohort: an observational cohort study. The Lancet. 2013;382:S8.

Chung JR, Kim SS, Flannery B, et al. Vaccine-associated attenuation of subjective severity among outpatients with influenza. Vaccine. 2022;40:4322–4327.

Fragaszy EB, Warren-Gash C, White PJ, et al. Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: Results from the Flu Watch cohort study. Influenza Other Respir Viruses. 2018;12:171–182.

Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics. 2001;19:293–301.

Hollmann M, Garin O, Galante M, et al. Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients. PLoS One. 2013;8:e60477.

Mao Z, Li X, Korsten K, et al. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults. J Infect Dis. 2022;226:S87-S94.

O'Brien BJ, Goeree R, Blackhouse G, et al. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health. 2003;6:116–125.

Osborne R, Hawthorne G, Papanicolaou M, et al. Measurement of rapid changes in health outcomes in people with influenza symptoms. Journal of Drug Assessment. 2000;3:205–220.

Pradas Velasco R, Villar FA, Puy Martínez-Zárate M. Utilización del cuestionario European Quality of Life-5 Dimensions (EQ-5D) para valorar la variación de la calidad de vida relacionada con la salud debida a la gripe [Use of European Quality of Life-5 Dimensions (EQ-5D) questionnary to value the health related quality of life variation because of influenza]. Gac Sanit. 2009;23:104–108.

Rombach I, Wang K, Tonner S, et al. Quality of life, healthcare use and costs in 'at-risk' children after early antibiotic treatment versus placebo for influenza-like illness: within-trial descriptive economic analyses of the ARCHIE randomised controlled trial. BMJ Open. 2022;12:e049373.

Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults. J Gen Intern Med. 2003;18:808–815.

Thorrington D, Balasegaram S, Cleary P, et al. Social and Economic Impacts of School Influenza Outbreaks in England: Survey of Caregivers. J Sch Health. 2017;87:209–216.

Tsuzuki S, Yoshihara K. The characteristics of influenza-like illness management in Japan. BMC Public Health. 2020;20:568.

Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7:iii-iv, xi-xiii, 1-170.

van Hoek AJ, Underwood A, Jit M, et al. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One. 2011;6:e17030.

Vindt Holm M, Gyldmark M, Holme Hansen E. Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults. Pharm World Sci. 2004;26:339–345.

Yang J, Jit M, Zheng Y, et al. The impact of influenza on the health related quality of life in China: an EQ-5D survey. BMC Infect Dis. 2017;17:686.